Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A
Fredrick Chalinga/LinkedIn
May 19, 2026, 16:24

Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A

Fredrick Chalinga, Medical Technologist at Aga Khan University Hospital, shared on LinkedIn:

”When Factor VIII Becomes the Enemy: The Science Behind Recombinant Factor VIIa in Hemophilia A

One of the greatest challenges in coagulation medicine is not the absence of clotting factors alone…but when the body develops inhibitors against the very treatment meant to save it.

In severe Hemophilia A, patients lack functional Factor VIII (FVIII).

Standard therapy involves FVIII replacement. However, repeated exposure may trigger the immune system to produce FVIII inhibitors (neutralizing antibodies), rendering infused FVIII ineffective.

So how do clinicians achieve hemostasis when Factor VIII can no longer function?

The answer lies in Recombinant Activated Factor VII (rFVIIa) — a powerful bypassing agent.

Why rFVIIa Works in the Presence of FVIII Inhibitors

Under normal physiology:

  • Factor VIII acts as a cofactor for Factor IXa
  • Together they form the intrinsic tenase complex.
  • This complex activates Factor X to Xa
  • Xa then converts prothrombin to thrombin, ultimately forming fibrin clot

But when FVIII inhibitors are present:

  • The intrinsic pathway is blocked
  • Adequate thrombin generation fails
  • Bleeding persists despite FVIII infusion

This is where rFVIIa becomes clinically crucial.

Mechanism of Action of rFVIIa
Recombinant activated Factor VII directly activates Factor X on the activated platelet surface, largely bypassing the need for:

  • Factor VIII
  • Factor IX
  • Intrinsic tenase complex

This generates a ‘thrombin burst’, leading to:

  • Stable fibrin clot formation
  • Improved hemostasis
  • Control of life-threatening bleeding episodes

Why It’s Called a ‘Bypassing Agent’
Because rFVIIa essentially circumvents the blocked intrinsic pathway and utilizes an alternative route to generate thrombin.

Instead of repairing the defective pathway, it simply goes around it.
That is advanced coagulation therapeutics in action.

Clinical Importance

  • rFVIIa is especially valuable in:
  • Hemophilia A with high-titer FVIII inhibitors
  • Surgical bleeding control
  • Trauma-associated bleeding in inhibitor patients
  • Emergency hemostatic management

Commonly known product: NovoSeven

Key Hemostasis Concept
Hemostasis is not always about replacing the missing factor-sometimes it’s about bypassing the blocked pathway entirely.”

Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A

Stay updated with Hemostasis Today.

bleeding disorders Fredrick Chalinga FVIII Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine NovoSeven Recombinant Factors
NewsFeed